A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma

Journal:

Science Translational Medicine

Published:

2026-01-28

DOI:

10.1126/scitranslmed.adt1211

Affiliations:

6

Authors:

20

Go to article

Institutions	Authors	Share
UVA Health System, United States of America (USA)	13.000000 13.000000	0.65
University of Virginia (UVA), United States of America (USA)	3.000000	0.15
Massachusetts Institute of Technology (MIT), United States of America (USA)	2.000000	0.10
Harvard Medical School (HMS), United States of America (USA)	1.500000	0.08
Deep Origin, United States of America (USA)	0.500000	0.03

Interested in Oncology and Carcinogenesis?